E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Abdominal Aortic Aneurysm |
|
E.1.1.1 | Medical condition in easily understood language |
Swelling of the largest blood vessel in the body |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064848 |
E.1.2 | Term | Chronic kidney disease |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
An abdominal aortic aneurysm is a swelling of the main blood vessel that supplies the organs in the abdomen and the legs. It most commonly occurs just below the kidneys (approximately at the level of the belly button). It is not yet clear why some people develop aneurysms but they are more common in smokers and in men. Abdominal aortic aneurysms are dangerous because they can rupture and if this happens up to 90% of people affected will die. Of those who make it to hospital, they have a less than 50% chance of surviving. At present, we use size, measured by an ultrasound scan, to best predict which abdominal aortic aneurysms are most likely to rupture. The problem with this is that sometimes small abdominal aortic aneurysms rupture and large abdominal aortic aneurysms go on to grow to 10cm without rupturing. This suggests that size is not the only factor to cause abdominal aortic aneurysms to grow and rupture. The principal objective of this study is to use magnetic resonance |
|
E.2.2 | Secondary objectives of the trial |
This study will look at patients under surveillance for abdominal aortic aneurysms. We will evaluate the uptake of the new imaging agent into the wall of the aneurysm, using an magnetic resonance imaging scan to see if this: 1. correlates with the rate of expansion of the abdominal aortic aneurysm. 2. occurs more commonly in patients who progress to surgery or whose aneurysm subsequently ruptures 3. relates to the amount of stress the abdominal aortic aneurysm is under from the force of blood pushing against it and whether this can predict which abdominal aortic aneurysm will grow at a faster or slower rate. 4. can provide a predictor of risk in addition to standard risk markers, such as smoking and high blood pressure. 5. occurs in a reproducible manner. 6. relates to the degree of new vessel formation and inflammation and how this contributes to abdominal aortic aneurysm growth rate. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Abdominal aortic aneurysms measuring ≥40mm in anteroposterior diameter on ultrasound scanning. 2. Age ≥40 years. Patients with abdominal aortic aneurysms less than 40 years may have a connective tissue disorder and a different aetiology to their disease. |
|
E.4 | Principal exclusion criteria |
1. Patients expected to undergo imminent elective or emergency surgical or endovascular repair. 2. Contraindication to magnetic resonance imaging scanning identified from magnetic resonance imaging safety questionnaire, which includes but not limited to: - intracranial aneurysm clips (except Sugita) or other metallic objects - history of intra-orbital metal fragments that have not been removed - pacemakers, implantable cardiac defibrillators and non-MR compatible heart valves - inner ear implants - history of claustrophobia in MR - allergy to MRI contrast enhancement agent 3. Patients refusing or unable to give informed consent 4. Woman with child-bearing potential will not be enrolled into the trial (woman who have experienced menarche, are pre-menopausal, have not been sterilised or who are currently pregnant). 5. Intercurrent illness including patients with a systemic inflammatory disorder or underlying malignancy (life expectancy < 2 years). 6. Renal dysfunction (eGFR ≤30 mL/min/1.73m2). 7. Polycythemia. 8. Contraindication to ferumoxytol (evidence of iron overload, known hypersensitivity to ferumoxytol or its components or anaemia not caused by iron deficiency). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To determine whether mural uptake of USPIO provides incremental risk prediction in addition to standard risk markers such as aneurysm diameter, smoking and blood pressure. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. The correlation between rate of aneurysm expansion and mural uptake of USPIO on MRI scanning. 2. To identify whether mural uptake of USPIO in MRI scanning occurs more commonly in patients who progress to surgery or whose aneurysm subsequently ruptures 3. The correlation between areas of biomechanical stress and mural uptake of USPIO on MRI scanning. 4. To identify whether mural uptake of USPIO in MRI scanning occurs in a reproducible manner. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Points 1-3: 24 months follow up. Point 4: evaluation at 1 month and 1 year. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |